Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q4 FY26 Earnings Presentation
18 slides from Ngl Fine-chem's earnings presentation, May 22, 2026
Slide 1: Regulation 30 Cover Letter to Stock Exchanges
Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 2663 6450, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884,Website www.nglfinechem.com May 22, 2026 BSE Limited National Stock Exchange of India Limited Phiroz
Slide 2: NGL Fine-Chem Limited Investor Presentation Q4 & FY26
NGL Fine-Chem Limited INVESTOR PRESENTATION Q4 & FY26
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 4: Inside This Presentation
Inside Pg. No. Pg. No. This Presentation 04 10 Q4 & FY26 Over view, Highlights Key Strengths and Strategy Pg. No. 15 Historical Financial Performance
Slide 5: Q4 & FY26 Highlights
01 Q4 & FY26 Highlights 05 M A N A G E M E N T C O M M E N TA R Y 06 Q U A R T E R LY O P E R AT I O N A L M E T R I C S 07 S U M M A R Y O F P R O F I T A N D LO S S S TAT E M E N T 08 SUMMARY OF BAL ANCE SHEET 09 S U M M A R Y O F C A S H F LO W S TAT E M E N T
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, “Q4FY26 deliver ed strong performance, movements in the forex markets lead to mark to characterized by a sharp uptick in sales driv en market provisions further depressing the margins. In entirely by volume expansion. This marks our third addition, shortages
Slide 7: Quarterly Operational Metrics
Quarterly Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q4FY25 Q3FY26 Q4FY26 PARTICULARS Q4FY25 Q3FY26 Q4FY26 ANIMAL API 90% 92% 95% TOP 3 PRODUCTS 33% 28% 29% HUMAN API 7% 2% 2% TOP 5 PRODUCTS 50% 44% 44% INTERMEDIATES 1% 4% 1% TOP 10 PRODUCTS 72% 65% 66% FORMULATIONS
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ IN CRORES PARTICUL ARS Q4FY25 Q3FY26 Q4FY26 Q-o-Q Y-o-Y FY25 FY26 Y-o-Y REVENUE FROM OPERATIONS 94.97 127.51 149.23 17.04% 57.13% 368.26 500.95 36.03% OTHER INCOME -0.97 4.61 2.46 46.67% -354.68% 8.63 14.73 70.65% TOTAL INCOME 94.01 132.12 151.69 14.81% 61.36%
Slide 9: Summary of Balance Sheet
Summary of Balance Sheet ₹ IN CRORES PARTICUL ARS FY25 FY26 SHAREHOLDERS FUND 282.43 329.23 NON CURRENT LIABILITIES 31.99 66.25 LONG TERM BORROWINGS 25.34 56.40 CURRENT LIABILITIES 118.97 150.01 SHORT TERM BORROWINGS 48.00 52.02 TOTAL EQUITY AND LIABILITIES 433.39 545.50 NON CURRENT ASSETS 198.01 26
Slide 10: Summary of Cash Flow Statement
Summary of Cash Flow Statement ₹ IN CRORES PARTICUL ARS FY25 FY26 CASH FLOW FROM OPERATING ACTIVITIES 32.36 43.32 CASH FLOW FROM INVESTING ACTIVITIES (69.68) (70.59) CASH FLOW FROM FINANCING ACTIVITIES 37.46 29.55 NET CASH FLOW 0.14 2.27 CASH AT THE BEGINNING OF YEAR 0.40 0.53 CASH AT THE END OF YEA
Slide 11: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 11 L E A D I N G A N I M A L H E A LT H C O M PA N Y 12 LEADERSHIP IN VETERINARY API SEGMENT 13 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA B I L I T I E S 14 S T R AT E G Y F O R N E X T L E G O F G R O W T H
Slide 12: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 45 APIs (43 Veterinary • Market leadership in • 3 state of the art • Strong presence • ~451 customers APIs, 2 Human
Slide 13: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT API SEGMENT CONCENTRATION Strong controls of processes with 95% in-house manufacturing and (₹ IN CRORES) 13% CAGR (OF SALES FY26) backward integrated facilities leading to cost competitiveness FY26 466 CUSTOMER PRODUCT F
Slide 14: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 5 manufacturing facilities located at Tarapur & Navi 20,000 m 2 168 kl 253 kl AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are ca
Slide 15: Strategy for next leg of growth
Strategy for next leg of growth BROWNFIELD EXPANSION • Completed expansion in ONGOING INITIATIVES subsidiary Macrotech a TO INCREASE • Additional capacities of CAPACITIES TO MEET intermediates GROWING DEMAND • Commercial production started GREENFIELD EXPANSION AT TARAPUR • Capacity expansion with su
Slide 16: Historical Financial Performance
03 Historical Financial Performance 16 ROBUST FINANCIAL PERFORMANCE
Slide 17: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES) FY26 501 FY26 73 FY26 48 FY25 368 FY25 34 FY25 21 FY24 339 FY24 53 FY24 41 FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 0 100 200 300 400 500 600 0 10 20 30 40 50 60 70 80 0 10 20 30 40 50 60 GROSS MARGIN
Slide 18: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Shivam Gharat Abhishek Mehra Thank You NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 301, E-square, Subhash Road, Vile Parle (East), Mumbai - 400057, Maha